{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:44:25Z","timestamp":1783021465665,"version":"3.54.6"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.amjcard.2022.10.057","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:01:36Z","timestamp":1671494496000},"page":"S2-S10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S1","title":["Current Understanding of Systemic Amyloidosis and Underlying Disease Mechanisms"],"prefix":"10.1016","volume":"185","author":[{"given":"Maria M.","family":"Picken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2022.10.057_bib0001","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","article-title":"Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","author":"Benson","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0002","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000506696","article-title":"The pathology of amyloidosis in classification: a review","volume":"143","author":"Picken","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0003","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/ndt\/gfw305","article-title":"Systemic amyloidosis: novel therapies and role of biomarkers","volume":"32","author":"Nuvolone","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-biochem-061516-045115","article-title":"Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade","volume":"86","author":"Chiti","year":"2017","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0005","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from A (AA) to T (ATTR): a review","volume":"289","author":"Muchtar","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0006","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1080\/13506129.2019.1597342","article-title":"The nomenclature committee of the international society of amyloidosis: back towards \u201cgreen birefringence","volume":"26","author":"Howie","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0007","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0008","first-page":"7482","article-title":"Nodular pulmonary amyloidosis and obvious ossification due to primary pulmonary MALT lymphoma with extensive plasmacytic differentiation: report of a rare case and review of the literature","volume":"8","author":"Xiang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0009","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.mayocp.2017.02.016","article-title":"Presentation and outcomes of localized immunoglobulin light chain amyloidosis: the Mayo Clinic experience","volume":"92","author":"Kourelis","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0010","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0012","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1750-1172-7-54","article-title":"Centre national de r\u00e9f\u00e9rence pour l'amylose AL et les autres maladies par d\u00e9p\u00f4ts d'immunoglobulines monoclonales. Al amyloidosis","volume":"7","author":"Desport","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0013","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2014-12-618108","article-title":"Hereditary systemic immunoglobulin light-chain amyloidosis","volume":"125","author":"Benson","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","article-title":"AL amyloidosis: from molecular mechanisms to targeted therapies","volume":"2017","author":"Merlini","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0015","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0016","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2014.104109","article-title":"Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)","volume":"99","author":"Jaccard","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0017","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2014.227","article-title":"Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients","volume":"28","author":"Palladini","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0018","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.bbmt.2015.04.001","article-title":"Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: results of a prospective clinical trial","volume":"21","author":"Sanchorawala","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0019","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MNH.0000000000000695","article-title":"Diagnosis of amyloid beyond Congo red","volume":"30","author":"Picken","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000507724","article-title":"Nonchemotherapy treatment of immunoglobulin light chain amyloidosis","volume":"143","author":"Van Doren","year":"2020","journal-title":"Acta Haematol"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2022.10.057_bib0021","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1182\/blood-2019-124482","article-title":"Results of the Phase 3 VITAL study of NEOD001 (birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for Mayo stage IV patients","volume":"134","author":"Gertz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0022","doi-asserted-by":"crossref","first-page":"e52686","DOI":"10.1371\/journal.pone.0052686","article-title":"AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils","volume":"7","author":"Wall","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0023","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12872-021-02407-6","article-title":"Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study","volume":"22","author":"Wechalekar","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0024","doi-asserted-by":"crossref","first-page":"eaan3128","DOI":"10.1126\/scitranslmed.aan3128","article-title":"Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis","volume":"10","author":"Richards","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0025","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jchf.2019.07.007","article-title":"A changing landscape of mortality for systemic light chain amyloidosis","volume":"7","author":"Barrett","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0026","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0027","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0028","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","article-title":"Geographic disparities in reported US amyloidosis mortality from 1979 to 2015: potential underdetection of cardiac amyloidosis","volume":"3","author":"Alexander","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0029","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS \u2013 the transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0031","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0032","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","article-title":"Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis","volume":"19","author":"Cavalcante","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0033","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0036","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0037","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0038","unstructured":"Clinical Review Report: tafamidis (Vyndaqel): (Pfizer Canada ULC): indication: for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or hereditary, to reduce cardiovascular mortality and cardiovascular-related hospitalization [internet]. Canadian Agency for Drugs and Technologies in Health. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563057\/. Accessed on July 1, 2022."},{"key":"10.1016\/j.amjcard.2022.10.057_bib0039","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0040","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/heartjnl-2016-310704","article-title":"Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response","volume":"103","author":"Grogan","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0041","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0042","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.rdc.2018.06.004","article-title":"Secondary, AA, amyloidosis","volume":"44","author":"Papa","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0043","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/13506129.2017.1342235","article-title":"Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre","volume":"24","author":"Lane","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0044","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/CLEP.S39981","article-title":"Systemic AA amyloidosis: epidemiology, diagnosis, and management","volume":"6","author":"Real de As\u00faa","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2019.1693359","article-title":"Causes of AA amyloidosis: a systematic review","volume":"27","author":"Brunger","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0046","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0047","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/ndt\/gfm684","article-title":"Immunopathology Group of the Italian Society of Nephrology. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome","volume":"23","author":"Bergesio","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0048","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ki.2008.152","article-title":"Leukocyte chemotactic factor 2: a novel renal amyloid protein","volume":"74","author":"Benson","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0049","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/ki.2014.11","article-title":"Clinical, morphologic, and genetic features of renal leukocyte chemotactic factor 2 amyloidosis","volume":"86","author":"Larsen","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0050","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2013-07-517938","article-title":"Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States","volume":"123","author":"Mereuta","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0051","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/modpathol.2016.29","article-title":"Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians","volume":"29","author":"Larsen","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0052","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ki.2014.45","article-title":"Alect2 amyloidosis: primum non nocere (first, do no harm)","volume":"86","author":"Picken","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0053","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2215\/CJN.12551214","article-title":"Leukocyte cell-derived chemotaxin 2-associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics","volume":"10","author":"Nasr","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0054","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/ki.2013.558","article-title":"Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis","volume":"86","author":"Said","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0055","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0056","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0057","doi-asserted-by":"crossref","unstructured":"Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis [published online August 5, 2022]. Cardiovasc Res 2022;cvac119. https:\/\/doi.org\/10.1093\/cvr\/cvac119","DOI":"10.1093\/cvr\/cvac119"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0058","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0059","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/13506129.2021.1994386","article-title":"Tissue biopsy for the diagnosis of amyloidosis: experience from some centres","volume":"29","author":"Benson","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0060","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020712-163913","article-title":"AA amyloidosis: pathogenesis and targeted therapy","volume":"10","author":"Westermark","year":"2015","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0061","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1106180","article-title":"Proteotoxicity and cardiac dysfunction\u2013Alzheimer's disease of the heart?","volume":"368","author":"Willis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0062","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1100\/tsw.2011.64","article-title":"Recent insights into the pathogenesis of type AA amyloidosis","volume":"11","author":"van der Hilst","year":"2011","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211983","article-title":"Amyloid fibril composition within hereditary Val30Met (p. Val50Met) transthyretin amyloidosis families","volume":"14","author":"Suhr","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0064","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.hoc.2020.07.003","article-title":"The process of amyloid formation due to monoclonal immunoglobulins","volume":"34","author":"Morgan","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0065","first-page":"346564","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0066","first-page":"131","article-title":"Quantitative serum free light chain assay\u2013analytical issues","volume":"30","author":"Tate","year":"2009","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0067","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/2040620712466863","article-title":"Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions","volume":"4","author":"Tosi","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0068","doi-asserted-by":"crossref","first-page":"10664","DOI":"10.1039\/C8CC04396E","article-title":"Immunoglobulin light chain amyloid aggregation","volume":"54","author":"Blancas-Mejia","year":"2018","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0069","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0070","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B-cell clones","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0071","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Hum Mutat"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0072","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.3390\/ijms22094429","article-title":"Transthyretin misfolding, a fatal structural pathogenesis mechanism","volume":"22","author":"Si","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0073","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"Sattianayagam","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0074","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans","volume":"22","author":"Jacobson","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12265-015-9613-9","article-title":"Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis","volume":"8","author":"Damy","year":"2015","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0076","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/TCRM.S219979","article-title":"Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care","volume":"16","author":"Luigetti","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0077","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2147\/DDDT.S289772","article-title":"Drug discovery and development in rare diseases: taking a closer look at the tafamidis story","volume":"15","author":"Burton","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0078","doi-asserted-by":"crossref","first-page":"e13504","DOI":"10.1111\/eci.13504","article-title":"The long and winding road to target protein misfolding in cardiovascular diseases","volume":"51","author":"Diteepeng","year":"2021","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0079","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.1141448","article-title":"Adapting proteostasis for disease intervention","volume":"319","author":"Balch","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0080","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.devcel.2017.12.020","article-title":"A futile battle? Protein quality control and the stress of aging","volume":"44","author":"Higuchi-Sanabria","year":"2018","journal-title":"Dev Cell"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0081","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.yjmcc.2013.12.015","article-title":"Proteotoxicity: an underappreciated pathology in cardiac disease","volume":"71","author":"Sandri","year":"2014","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.057_bib0082","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.neuro.26.010302.081142","article-title":"Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders","volume":"26","author":"Caughey","year":"2003","journal-title":"Annu Rev Neurosci"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914922011754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914922011754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:07:25Z","timestamp":1762078045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914922011754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":82,"alternative-id":["S0002914922011754"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2022.10.057","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Understanding of Systemic Amyloidosis and Underlying Disease Mechanisms","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2022.10.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}